Close
What would you like to look for?
Site search
Search filters

DomoSafety SA closes a Serie B financing round

9 June 2021

DomoSafety SA, a leading company in the digital health segment, announced the successful closing of its Series B financing round.

Faveeo SA closes a Series B financing round

9 June 2021

Faveeo SA, a Swiss start-up, announced the successful closing of its Series B financing round.

Haya Therapeutics completes CHF 18m Seed Financing Round

21 May 2021

HAYA Therapeutics SA announced the successful closing of its CHF 18m seed round.

Oculis closes an oversubscribed USD 57m Series C financing round

6 May 2021

Oculis S.A., a late-stage biopharmaceutical company, focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, has closed an oversubscribed USD 57m Series C financing round.

First closing of EUR 130m by MTIP

6 April 2021

Basel-based MTIP, a private equity firm focusing on digital health and connected medical device companies, has completed a first closing of EUR 130m...

Majority stake of STIMIT sold to Dräger

6 April 2021

The Swiss-based start-up medical technology company STIMIT AG was founded in 2018...

CITIC becomes largest shareholder in MedAlliance

22 March 2021

Trustar Capital (formerly known as CITIC Capital Partners), a private equity affiliate of CITIC Capital Holdings Limited, has completed its over USD 50.0m investment in the Switzerland based global leading medical technology company MedAlliance SA ("MedAlliance"), becoming MedAlliance's single largest shareholder.

exceet Card Group acquires Intercard

15 January 2021

exceet Card Group, a leading European provider of smart card solutions, acquired Intercard Holding AG, a leading Swiss provider of smart card solutions.

Steele acquires Info4C

14 December 2020

The US data compliance provider Steele has acquired the Swiss Info4C AG. Info4C is the global provider of high-quality compliance information.

Sale of NBE-Therapeutics to Boehringer Ingelheim for EUR 1.18bn

11 December 2020

Boehringer Ingelheim and the shareholders of NBE-Therapeutics have signed a share purchase agreement with a total transaction value of EUR 1.18bn which also includes contingent clinical and regulatory milestones.